Browsing Tag
Indian biotech sector
1 post
Anthem Biosciences (NSE: ANTHEM) Q2 FY26 results: Can strong CRDMO tailwinds keep driving profitability?
Anthem Biosciences Q2 FY26 results reveal strong CRDMO-led growth and 44.5% EBITDA margins. Find out what’s driving investor sentiment and what’s next.